Developing new tools for cancer treatment using DNA-based methods
Harnessing the In Vitro Selection for Activity-based Proteomics and Chemical Probe Development
['FUNDING_OTHER'] · PURDUE UNIVERSITY · NIH-11003281
This study is exploring new ways to fight cancer by finding special molecules that can block certain proteins that help cancer grow, which could lead to better treatments for patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | PURDUE UNIVERSITY (nih funded) |
| Locations | 1 site (WEST LAFAYETTE, UNITED STATES) |
| Trial ID | NIH-11003281 on ClinicalTrials.gov |
What this research studies
This research focuses on creating innovative tools for cancer therapy by utilizing DNA-encoded chemical libraries and enzyme activity probes. By employing in vitro selection assays, the project aims to identify and develop inhibitors that target specific proteins involved in cancer progression. These inhibitors will help researchers understand the roles of these proteins in disease and could lead to new therapeutic options. The methodology involves analyzing drug molecule activity and biochemical interactions through advanced DNA analysis techniques.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cancers that involve the chromobox and bromodomain proteins.
Not a fit: Patients with cancers unrelated to the targeted proteins or those who are not eligible for experimental therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new cancer therapies that are more effective and targeted.
How similar studies have performed: Other research has shown promise in using DNA-encoded libraries for drug discovery, indicating that this approach has potential for success.
Where this research is happening
WEST LAFAYETTE, UNITED STATES
- PURDUE UNIVERSITY — WEST LAFAYETTE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KRUSEMARK, CASEY JOHN — PURDUE UNIVERSITY
- Study coordinator: KRUSEMARK, CASEY JOHN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy